Actin is used as an internal control for protein loading. The histological subtype, when identified for these cell lines in previous studies 40, 41 , is also indicated as: S=Serous, MS= Mixed Serous, M=Mixed, ND: not determined. SKOV3 (TP53 null) and IGROV-1 (TP53 mutated), of serous histotype, exhibit high levels of MAP3K8 protein and have been used for further analyses. (B) Scatter plot of MAP3K8 protein levels in 108 HGSC tumour samples, as assessed by densitometry analyses of western blots (as shown in Figure 4A ). Two subgroups of HGSC patients have been defined, as low-MAP3K8 (N=54 patients) or high-MAP3K8 (N=54 patients) based on the median (=0.9). P-value is based on Student's t-test. (C) Left: Representative western blot showing MAP3K8 protein levels in stable cell lines (shCtrl, shMAP3K8_1 and shMAP3K8_2) derived from SKOV3 and IGROV-1. Actin is used as an internal control for protein loading. Right: Bar plots of MAP3K8 protein levels in stable cell lines (shCtrl, shMAP3K8_1 and shMAP3K8_2), assessed by densitometry analyses of western blots, as shown in Left (n=3 independent experiments). P-values are based on Student's t-test. Data are shown as means ± s.e.m. The mean values obtained for parental SKOV3 and IGROV-1 cell lines (mean value =1.4 for SKOV3 and 2.2 for IGROV-1) are above 0.9, the median of MAP3K8 integrated density separating low-and high-MAP3K8 HGSC tumour samples (as shown in B). Moreover, the mean values obtained for shMAP3K8_1 and shMAP3K8_2 stable cell lines derived from SKOV3 and IGROV-1. 
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Supplementary Figure 4: MAP3K8 inhibition by KI treatment does not affect JNK, p38MAPK
and NF-κB p65 pathway reproducibly in ovarian cancer cell lines (A) Representative western blots showing MAP3K8, P-JNK, JNK, P-NFκB, NFκB, P-p38, and p38 protein levels upon serum (FBS) stimulation for the indicated times in SKOV3 and IGROV-1 ovarian cancer cell lines treated prior to FBS stimulation either with MAP3K8 kinase inhibitor (KI) or with the vehicle medium for KI (DMSO). Actin is used as an internal control for protein loading. (B) Bar plots showing P-JNK/JNK, P-NFκB/NFκB, P-p38/p38 ratios, as assessed by densitometry analysis of western blots (as shown in A) obtained from independent experiments and expressed as fold change compared to the DMSO t=0h time point. P-values are based on Student's t-test. Data are shown as means ± s.e.m (n=3 independent experiments). (C) Bar plots showing MAP3K8 protein levels following serum induction of SKOV3 and IGROV-1 ovarian cancer cells, as indicated. Are considered either both p58 (kDa) and p52 (kDa) MAP3K8 isoforms (black), or each isoform (p58, dark grey or p52, light grey), as assessed by densitometry analysis of western blots (as shown in A) and expressed as fold change compared to t=0h time point.
Supplementary
Figure 5: MAP3K8 silencing using shRNA does not affect JNK, p38MAPK and NF-κB p65 pathway reproducibly in ovarian cancer cell lines (A) Representative western blots showing MAP3K8, P-JNK, JNK, P-NF-κB, NF-κB, P-p38, and p38 protein levels in stable cell lines (shCtrl, shMAP3K8_1 and shMAP3K8_2) derived from SKOV3 and IGROV-1 cancer cells and kept without serum (-FBS) or stimulated by serum (+FBS). Actin is used as an internal control for protein loading. (B) Bar plots showing P-JNK/JNK, P-NF-κB/NF-κB, P-p38/p38 ratios, as assessed by densitometry analysis of western blots (as shown in A). P-values are based on Student's t-test. Data are shown as means ± s.e.m (n≥3 independent experiments). Portions of these western blots are shown in Figure 5A . (E) Portions of these western blots are shown in Figure 5D . All the other blots shown in Figures 3C,3G , 4D and 4F are full blots. Patients were treated with a combination of surgery and chemotherapy, the latter including alkylating or alkylating-like agents ± taxane as a first line treatment in most cases. Clinical response was evaluated according to tumour mass evolution by monitoring patients throughout the chemotherapeutic treatment. 56 subjects (40.3%) had a complete response to treatment and 48 subjects (34,5%) had a partial response or progression. Complete response was defined as complete disappearance of the disease up to 6 months after treatment. In patients with incomplete response, the disease does not significantly decrease or even progress during treatment, or shows recurrence within 6 months of treatment completion. All the subjects underwent surgery, 94 of them have a non-optimal surgery and 41 subjects have an optimal surgery. 115 patients (82.7%) relapsed with a median delay of relapse of 24 months (with a range of 0.1-243 months). Inactivation of genes associated with homologous recombination repair or BRCA1 methylation (BRCAness status) were defined by large-scale state transitions, referring to as chromosomal breaks between adjacent regions of at least 10 Mb, which are robust indicator of BRCAness status in ovarian and basal-like breast cancers 68 .
